ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pirfenidone

Also written as “Pirfenidone”, “Pirfenidone Modified-Release Tablets” and “Deupirfenidone”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Lung Injury · Lung Diseases, Interstitial · Pulmonary Fibrosis · COVID-19, led by 6 companies.

Drug pagePirfenidone: every studyMany companies study it; this page follows only the 29 they lead. All 102 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 4, 201529 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only120 open or runningphase 4since Nov 4, 2015Mar 24, 2004none ahead
GNI Groupits history only72 open or runningphase 3since Feb 26, 2019Nov 18, 2014Dec 30, 2026phase 3 · NCT07388680
PureTech52 open or runningphase 3since Dec 8, 2025Jan 21, 2020Nov 2029phase 3 · NCT07284602
Overseas Pharmaceuticalsits history only30 open or runningphase 1since Aug 22, 2024Aug 22, 2024none ahead
beijing-kawin-technology-share-holding-co-ltdits history only10 open or runningphase 2since Dec 30, 2011Dec 30, 2011none ahead
grupo-medifarma-s-a-de-c-vits history only10 open or runningphase 3since Jul 6, 2015Jul 6, 2015none ahead

Also a collaborator on its studies: Clinipace Worldwide, Novotech (Australia) Pty, Shanghai Genomics and GNI-EPS Pharmaceuticals, Inc. (GNI Group).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 21, 2020First study: phase 2 study in LymphedemaFirst studyNCT04243837 · 50 enrolled · United States, Australia
  2. Dec 2, 2020Phase 2 study in COVID-19NCT04652518 · 185 enrolled · United States, Argentina, Brazil and more
  3. Apr 2, 2022Phase 2 study in Idiopathic Pulmonary FibrosisNCT05321420 · 240 enrolled · United States, Argentina, Chile and more
  4. Dec 8, 2025Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedNCT07284602 · 1,100 planned · United States, Canada
  5. Feb 19, 2026Phase 1 study in Pharmacokinetic AnalysisNCT07456800 · 116 enrolled · United States

Ahead

  1. Nov 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07284602

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 PureTech leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07456800Pharmacokinetic Analysis · United States1CompletedJan 1, 2022116
NCT07284602Idiopathic Pulmonary Fibrosis · United States, Canada3RecruitingNov 20291,100
NCT05321420Idiopathic Pulmonary Fibrosis · United States, Argentina, Chile and more2Active, not recruitingOct 15, 2024240
NCT04652518COVID-19 · United States, Argentina, Brazil and more2TerminatedJun 28, 2022185
NCT04243837Lymphedema · United States, Australia2TerminatedSep 9, 202250

How it is read

Names in the registry

  • “Pirfenidone”, 26 entries
  • “Pirfenidone Modified-Release Tablets”, 4 entries
  • “Deupirfenidone”, 3 entries
  • “pirfenidone capsule”, 2 entries
  • “pirfenidone”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.